Delivery Order SPE2DB22D2005-SPE2DB26FJEF4
- Not listed
- The Defense Logistics Agency awarded a $6,405.26 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of HUMIRA (adalimumab) prefilled pens at 40 mg/0.4 ml dosage. This is a non-set-aside, competitively awarded contract with a completion date of September 29, 2025, and performance occurring at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a single transaction within AmerisourceBergen's broader federal...
- The Defense Logistics Agency awarded a $1,510.60 delivery order to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) prefilled pens at 40 mg/0.4 mL on June 3, 2025, with performance in Conshohocken, Pennsylvania. This is a firm fixed price, non-set-aside contract with a completion date of June 4, 2025. The delivery order represents a child award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and running through...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $4,745.11 by the Defense Logistics Agency on August 27, 2025, with completion scheduled for August 28, 2025. The contract, awarded without set-aside designation through competitive procurement, covers the supply of Humira (adalimumab) prefilled pen injections at 40 mg/0.4 mL dosage. The delivery order was issued under a firm fixed-price arrangement...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of HUMIRA (adalimumab) 40 mg/0.4 mL pre-filled pens, with a contract ceiling value of $2,265.90. This is a firm fixed-price, competitively awarded delivery order issued without a set-aside designation, with an ultimate completion date of August 13, 2025. The contract is performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $1,957.76 to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of HUMIRA (Adalimumab) prefilled pens at 40 mg/0.4 mL. This firm fixed-price delivery order represents a non-set-aside competitive award with an ultimate completion date of September 22, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as...
- The Defense Logistics Agency awarded a $11,604.67 firm fixed price delivery order to AmerisourceBergen Drug Corp on October 17, 2025, for the supply of Humira (adalimumab) pre-filled pens, 40 mg/0.4 mL formulation. The contract is non-set-aside and competitively awarded, with an ultimate completion date of October 20, 2025. AmerisourceBergen's Corporate Office in Conshohocken, Pennsylvania will serve as the place of performance for this delivery order, which is issued under the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) prefilled pens, 40 mg/0.4 mL formulation, valued at $6,797.70 with a firm fixed price structure. Awarded on September 15, 2025, this non-set-aside delivery order is scheduled for completion by September 16, 2025, with performance to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract issued under...
- The Defense Logistics Agency awarded a $20,755.70 delivery order to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) pen 40 mg/0.4 mL on June 30, 2025, with an ultimate completion date of July 1, 2025. This contract employs firm fixed-price pricing with no set-aside designation, indicating competitive award to this pharmaceutical distributor. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- The Defense Logistics Agency awarded a delivery order valued at $3,021.20 to AmerisourceBergen Drug Corp for the supply of HUMIRA (adalimumab) prefilled pens containing 40 mg/0.4 mL. This is a firm fixed-price contract with no set-aside designation, executed on June 3, 2025, with an ultimate completion date of June 4, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $4,531.80 delivery order to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) prefilled pens at 40 mg/0.4 mL. This is a firm fixed-price, competitively awarded contract with no set-aside designation, with a completion date of July 31, 2025. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters as a major pharmaceutical distributor serving federal healthcare...
- SPE2DB22D2005Indefinite Delivery Contract
- SPE2DB22D2005-SPE2DB26FJEF4Delivery Order
The Defense Logistics Agency awarded a $6,596.59 firm fixed price delivery order to AmerisourceBergen Drug Corp on October 21, 2025, for the supply of HUMIRA (adalimumab) prefilled pens at 40 mg/0.4 mL concentration. This is a non-set-aside contract with an ultimate completion date of October 22, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. As a child order under a larger contract vehicle, this delivery order leverages AmerisourceBergen Drug Corp's established relationship with the Defense Logistics Agency to provide critical pharmaceutical products to support federal healthcare systems, including the Defense Health Agency and other military medical supply chains. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, operates under a significant Indefinite Delivery Contract with DLA Troop Support Medical valued at $999,999,999.00 through December 2026. This prime vendor agreement enables the company to supply a comprehensive range of pharmaceuticals and medical supplies to support military healthcare programs globally. The company's track record of fulfilling federal procurement requirements through open competition, combined with its extensive portfolio of specialty medications and brand-name drugs, positions it as a critical vendor for federal medical procurement, particularly for military and veteran healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.6k | 10/21/25 |